¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"release phenomenon"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® rebound phenomenon ÇÑ±Û ¹Ý¹ßÇö»ó, ¹Ýµ¿Çö»ó
¼³¸í   
  ¼Ò³ú ±â´ÉÀå¾Ö¿¡¼­ »çÁöÀÇ ´ëÇ×±ÙÀ° »çÀÌÀÇ ÇùÁ¶¼º »ó½ÇÀǠ¡Èķμ­, È¯ÀÚ¿¡°Ô ¾çÆÈÀ» ¼öÆòÀ¸·Î »¸°Ô ÇÏ°í ±× ÆÈÀ» °­ÇϰԠġ¸é Á¤»óÀΠ°æ¿ì´Â °ð ¿ø»óÀ¸·Î ¿Ã¸®´Âµ¥ ºñÇÏ¿© È¯ÀÚ¿¡ À־´Â ¿øÀ§Ä¡·Î µ¹¾Æ¿À´Â µ¥ ¸î ¹øÀ̳ª ¶³°Ô µÈ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • airway pressure-release ventilation
    ±âµµ¾ÐÇØÁ¦È¯±â
  • delayed-release
    Áö¿¬ºÐºñ
  • pressure release ventilation
    ¾Ð·ÂÇØÁ¦È¯±â
  • release
    1. ¹æÃâ 2. ºÐºñ 3. ¹Ú¸®, À¯¸® 4. ÇØÁ¦ 5. ¹èÆ÷ 6. º¹±¸
  • release hallucination
    ¹æÃâȯ°¢
  • somatotropin release inhibiting factor
    ¼ºÀåÈ£¸£¸óºÐºñ¾ïÁ¦ÀÎÀÚ
  • aqueous-influx phenomenon
    ¹æ¼öÀ¯ÀÔÇö»ó
  • adoption phenomenon
    ä¿ëÇö»ó
  • clasp-knife phenomenon
    Á¢´ÂÄ®Çö»ó
  • closing-in phenomenon
    Á¾°áÇö»ó
  • critical phenomenon
    ÀÓ°èÇö»ó
  • crowding phenomenon
    ¹ÐÁýÇö»ó
  • cytopathogenic phenomenon
    ¼¼Æ÷º¯¼ºÇö»ó
  • centralization phenomenon
    Áß½ÉÈ­Çö»ó
  • duplication phenomenon
    º¹Á¦Çö»ó
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phenomenon
    Çö»ó
  • phantom phenomenon
    ÇêÇö»ó, ȯ»óÇö»ó
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • recruitment phenomenon
    Á¡ÁõÇö»ó, ´©°¡Çö»ó, º¸ÃæÇö»ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • airway pressure-release ventilation
    ±âµµ¾ÐÇØÁ¦È¯±â
  • deficient release reaction
    ¹æÃâ¹ÝÀÀ°áÇÌ
  • somatotropin release inhibiting factor
    ¼ºÀåÈ£¸£¸óÀ¯¸®¾ïÁ¦ÀÎÀÚ
  • release hallucination
    ¹æÃâȯ°¢
  • pressure release ventilation
    ¾Ð·ÂÇØÁ¦È¯±â
  • adoption phenomenon
    ä¿ëÇö»ó
  • aqueous-influx phenomenon
    ¹æ¼öÀ¯ÀÔÇö»ó
  • clasp-knife phenomenon
    Á¢´ÂÄ®Çö»ó
  • closing-in phenomenon
    Á¾°áÇö»ó
  • critical phenomenon
    ÀÓ°èÇö»ó
  • crowding phenomenon
    ¹ÐÁýÇö»ó
  • cytopathogenic phenomenon
    ¼¼Æ÷º¯¼ºÇö»ó
  • delay phenomenon
    Áö¿¬Çö»ó
  • discontinuity phenomenon
    ºÒ¿¬¼ÓÇö»ó
  • dissociative phenomenon
    ÇØ¸®Çö»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • release phenomenon
    À¯¸®Çö»ó.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ATP release
    »ïÀÎ»ê¾Æµ¥³ë½Å À¯¸®
  • histamine release test
    È÷½ºÅ¸¹ÎÀ¯¸®½ÃÇè
  • pressure release ventilation
    °¨¾ÐÅëdz,ȯ±â
  • release hallucination
    ¹æÃâȯ°¢(Û¯õóü³ÊÆ)
  • release of information and confidentiality
    Á¤º¸¿Í ºñ¹Ð´©¼³(ÝúÚËÒèàÜ)
  • Arthus phenomenon
    ¾Æ¸£Åõ½º Çö»ó(~ úÞßÚ)
  • Arthuss phenomenon
    ¾Æ¸£Åõ½ºÇö»ó
  • Bells phenomenon
    º§Çö»ó
  • CRST(Calcinosis, Raynauds phenomenon, Sclerodactyly, Telangiectasia) syndrome
    CRST ÁõÈıº.
  • Chameleon phenomenon
    Ä«¸á·¹¿ÂÇö»ó.
  • Danysz phenomenon
    Danysz Çö»ó
  • Danyszs phenomenon
    ´Ù´ÏÁî Çö»ó
  • Faraday s phenomenon
    ÆÐ·¯µ¥ÀÌÇö»ó.
  • Fowler phenomenon
    º¸ÃæÇö»ó
  • Gibbs phenomenon
    ±é½º Çö»ó
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • release phenomenon
    À¯¸®Çö»ó.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lupus erythematosus phenomenon = LE phenomenon
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ)
  • deficient release reaction
    ¹æÃâ¹ÝÀÀ°áÇÌ.
  • histamine release test
    È÷½ºÅ¸¹ÎÀ¯¸®½ÃÇè
  • leukocyte histamine release test
    ¹éÇ÷±¸È÷½ºÅ¸¹ÎºÐºñ½ÃÇè
  • pressure release ventilation
    °¨¾ÐÅëdz,ȯ±â
  • release hallucination
    ¹æÃâȯ°¢(Û¯õóü³ÊÆ)
  • release of information and confidentiality
    Á¤º¸¿Í ºñ¹Ð´©¼³(ÝúÚËÒèàÜ)
  • somatotropin release inhibiting facto
    ¼Ò¸¶Å䯮·ÎÇÉ ¹æÃâ¾ïÁ¦ ÀÎÀÚ.
  • sustained release drugs
    ÁöÈ¿¼º ¾àÁ¦(ò¥üùàõ å·ð¥).
  • sustained release drugs
    ÁöÈ¿¼º ¾àÁ¦(ò¥üùàõå·ð¥).
  • anamnestic phenomenon
    ±â¿ÕÇö»ó (¡­úÞßÚ).
  • anamnestic phenomenon
    ¸é¿ª[ÇÐÀû]±â¾ï[Çö»ó]
  • aqueous-influx phenomenon
    ¹æ¼öÀ¯ÀÔÇö»ó
  • arm phenomenon
    ÆÈ Çö»ó.
  • autoscopic phenomenon
    ÀÚ±âȯ¿µÇö»ó
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Sarle's phenomenon
    »ì·¹Çö»ó
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Danysz phenomenon
    ´ë´ÏÁî Çö»ó(úÞßÚ)
  • ectrokinetic phenomenon
    °è¸éµ¿Àü±â Çö»ó(Í£ØüÔÑï³Ñ¨úÞßÚ)
  • plateau phenomenon
    Ç÷¡Åä Çö»ó(úÞßÚ)
  • growth hormone release-inhibiting hormone
    ¼ºÀå(à÷íþ) È£¸£¸ó ¹æÃâÀúÇØ (Û¯õóîÁúª) È£¸£¸ó
  • prolactin release-inhibiting hormone
    ÇÁ·Ñ¶ôƾ À¯¸®ÀúÇØ(ë´×îîÁúª)È£¸£¸ó
  • protein release factor
    ´Ü¹éÁú ¹æÃâÀÎÀÚ(Ó±ÛÜòõÛ¯õóì×í­)
  • release factor
    À¯¸® ÀÎÀÚ(ë´×îì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • release
    À¯¸®, ¹æÃâ
  • entry phenomenon
    ÁøÀÔÇö»ó
  • entry slice phenomenon
    À¯ÀԴܸéÇö»ó
  • flare phenomenon
    Àå°³Çö»ó
  • Gibbs phenomenon
    ±é½ºÇö»ó
  • iceberg phenomenon
    ºù»ê Çö»ó
  • phenomenon
    Çö»ó
  • rebound phenomenon
    ¹Ýµ¿Çö»ó
  • slice entry phenomenon
    ÀýÆíÀÔ±¸Çö»ó
  • sunset phenomenon
    ÀϸôÇö»ó
  • time of flight phenomenon
    À¯Ã¼¼Óµµ°­Á¶Çö»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
CREST Syndrome   1. Calcinosis cutis
  2. Raynaud's phenomenon
  3. Esophageal ...
CRST Syndrome   1. Calcinosis
  2. Raynaud's Phenomenon
  3. Sclerodactyly
...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
VF   1) Ventricular Fibrillation
    ? Tx of Ventricular Fibrillation ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PRP Primary Raynaud's Phenomenon
RP Raynaud Phenomenon
APRV Airway Pressure Release Ventilation
BRP bacteriocin release protein
CICR Ca induced Ca release
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chromium-51 release test
    Å©·Î¹Å-51 ¹æÃâ ½ÇÇè
    »ì¾ÆÀÖ´Â ¼¼Æ÷¿¡
  • release factor
    ¹æÃâ ÀÎÀÚ
  • sustained release drug
    ÁöÈ¿¼º ¾àÁ¦
  • aldosterone escape phenomenon
    ¾Ëµµ½ºÅ×·Ð ¹èÃâ Çö»ó
    ¼¼Æ÷ ¿Ü¾×ÀÌ ¾î´À Á¤µµ Áõ°¡Çϸé aldosteroneÀÇ ºÐºñ°¡ °è¼Ó Áõ°¡ÇÏ´õ¶óµµ ³ªÆ®·ýÀÇ ¹è¼³ÀÌ Áõ°¡ÇÏ´Â Çö»óÀ» ¸»ÇÑ´Ù. ÀÌ Çö»óÀº ¼¼Æ÷ ¿Ü¾×ÀÇ Áõ°¡¿Í ÀϺδ ANH
  • aqueous-influx phenomenon
    ¹æ¼ö À¯ÀÔ Çö»ó
  • arthus phenomenon
    ¾Æ¸£Æ©½º Çö»ó
  • central pain phenomenon
    ÁßÃß¼º µ¿Åë Çö»ó
  • Chiristensen phenomenon
    Å©¸®½ºÅÙ¼¾ Çö»ó
    ÇϾÇÀÇ Àü¹æ¿îµ¿ ½Ã ´ëÇÕÇÏ´Â ±³ÇÕ¸é »çÀÌ¿¡ »ý±â´Â °£°Ý.
  • Christensen's phenomenon
    Å©¸®½ºÅÙ¼¾ Çö»ó
  • Class Switching phenomenon
    ºÐ·ù Àüȯ Çö»ó
    ÇϳªÀÇ B ¼¼Æ÷°¡ ±×¿¡ »óÀÀÇÒ ¼ö Àִ ƯÀÌ Ç׿ø¿¡ Á¢ÇÏ¿´À» ¶§ isoty
  • dawn phenomenon
    »õº® Çö»ó
    Á¦ 1Çü ´ç´¢º´ ȯÀÚÀÇ 75%¿¡¼­, ±×¸®°í ´Ù¼öÀÇ Á¦ 2Çü ´ç´¢º´ ȯÀÚ ¹× Á¤»óÀο¡¼­µµ ÀϾ´Ù. À̰ÍÀº ¿ÀÀü 5-8½Ã »çÀÌ¿¡ Àν¶¸°¿¡ ´ëÇÑ Á¶Á÷ÀÇ °¨¼ö¼ºÀÌ °¨¼ÒÇÏ¿© ÀϾ´Ù. ÃÖ±ÙÀÇ Áõ°Å´Â ÀÌ Çö»óÀÌ ¼ö¸é Áß¿¡ ¼ºÀå È£¸£¸ó ºÐºñÀÇ Áõ°¡¿¡ ÀÇÇÏ¿© À¯¹ßµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. »õº® Çö»óÀÌ ´Üµ¶À» ¹ß»ýÇϸé À̸¥ ¾ÆÄ§¿¡ °æµµÀÇ °íÇ÷´çÁõÀÌ ¿À³ª ¼Ò¸ð±â È¿°ú³ª °¨Åð Çö»óÀÌ µ¿¹ÝµÇ¸é °íÇ÷´çÁõÀº ½ÉÇØÁø´Ù.
  • dolls head phenomenon
    ÀÎÇü ¸Ó¸® Çö»ó, ÀÎÇü µÎ Çö»ó
  • flare phenomenon
    Àå°³ Çö»ó
  • Fowler phenomenon
    º¸Ãæ Çö»ó
  • iceberg phenomenon
    ºù»ê Çö»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
release phenomenon The increased tonus and hyperirritability of muscle-stretch reflexes which occur following damage of the upper portions of the extrapyramidal system.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
carpal tunnel release <orthopaedics, procedure> An orthopaedic surgical procedure which relieves the pressure exerted on the median nerve within the carpal tunnel in the wrist.
This surgery may be performed conventionally via a small incision or using a fibreoptic scope (endoscopic carpal tunnel repair).
(08 Jan 1998)
Release <chemical> Abscission agent for loosening citrus fruit before harvesting
Synonym: 5-chloro-3-methyl-4-nitro-1h-pyrazole
(26 Jun 1999)
release factor A component of the specialised transport system involved in the transport of cobalamin (vitamin B12) across the wall of the intestine. Dissociates the complex between cobalamin and the extracellular cobalamin binding glycoprotein known as intrinsic factor.
(18 Nov 1997)
melanotropin release-inhibiting hormone Inhibits synthesis and release of melanotropin.
Synonym: melanotropin release-inhibiting hormone.
Origin: melanotropin + G. States, stationary, + -in
(05 Mar 2000)
ryanodine receptor calcium release channel Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells.
(12 Dec 1998)
pituitary hormone release inhibiting hormones Polypeptide hormones produced in the hypothalamus which inhibit the release of pituitary hormones.
(12 Dec 1998)
msh release-inhibiting hormone <chemical> An oligopeptide hormone produced in the hypothalamus that inhibits the release of melanocyte-stimulating hormone (msh).
Chemical name: Melanostatin
(12 Dec 1998)
control release suture Eyeless suture with thread attached to needle such that the two separate when tension is applied to the thread.
(05 Mar 2000)
prolactin release-inhibiting hormone <chemical> A polypeptide hormone produced in the hypothalamus that inhibits the release of prolactin.
Chemical name: Prolactin release-inhibiting factor
(12 Dec 1998)
histamine release The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects.
(12 Dec 1998)
somatotropin release-inhibiting factor <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release.
(18 Nov 1997)
somatotropin release-inhibiting hormone <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release.
(18 Nov 1997)
deliberate release Generally refers to putting a genetically manipulated organism into field trials.
(14 Nov 1997)
sustained release tablet A drug product formulation that provides the required dosage initially and then maintains or repeats it at desired intervals.
Synonym: prolonged action tablet, repeat action tablet.
(05 Mar 2000)
adhesion phenomenon A phenomenon manifested by the adherence of antigen-antibody-complement complex to "indicator cells" (microorganisms, platelets, leukocytes, or erythrocytes), the reaction being sensitive and specific for the antigen and antibody in the complex.
Synonym: erythrocyte adherence phenomenon, immune adherence phenomenon, red cell adherence phenomenon.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • phenomenon
    »ç°Ç; Çö»ó
  • Raynaud's phenomenon
    ·¹À̳ë Çö»ó(¼ÕÀÇ ¼Òµ¿¸Æ ¼öÃà¿¡ ÀÇÇÑ ÀϽÃÀû Ç÷¾× ºÎÁ·À¸·Î ¼Õ°¡¶ô.¼ÕÀÇ ÀϺΰ¡ â¹éÇØ Áö´Â Çö»ó)
  • dellinger phenomenon
    µ¨¸°Àú Çö»ó 9
  • phenomenon
    Çö»ó;°æÀÌ;Áø±âÇÑ »ç¹°
  • release
    ¼®¹æÇÏ´Ù
  • day release
    (¿µ)¿¬¼ö ÈÞ°¡ Á¦µµ(Á¾¾÷¿ø¿¡°Ô ´ëÇÐ ´Ù´Ò ³·½Ã°£À» Çã¶ôÇØ ÁÖ´Â ÀÏ)
  • happy release
    °íÅëÀ¸·ÎºÎÅÍÀÇ ÇØ¹æ;Á×À½
  • news release
    PRESS RELEASE
  • press release
    (¹Ì¸® ³ª´©¾î ÁÖ´Â ¼º¸í¼­ µî) º¸µµÀÚ·á
  • release
    (ÅäÁö.°¡¿ÁµîÀ»)Àü´ëÇÏ´Ù;¾çµµÇÏ´Ù
  • release
    ³õ´Ù;Ç®¾î³õ´Ù;¶¼¾î ³õ´Ù;(ÆøÅºÀ»)ÅõÇÏÇÏ´Ù;(»ç¶÷.µ¿¹°À»)¼®¹æ(¹æ¸é)ÇÏ´Ù;³õ¾ÆÁÖ´Ù;ÇØ¹æ½ÃŰ´Ù;¸éÇÏ°Ô ÇÏ´Ù;ÇØÁ¦ÇÏ´Ù;¸éÁ¦ÇÏ´Ù;(¿µÈ­µîÀ»)°³ºÀÇÏ´Ù;(·¹ÄÚµåµîÀ»)¹ß¸ÅÇÏ´Ù;(´º½ºµîÀ»)¹ßÇ¥ÇÏ´Ù;°ø°³ÇÏ´Ù;(½Ä·áǰ.¹°ÀÚµîÀ»)¹æÃâÇÏ´Ù;(±Ç¸®µîÀ»)Æ÷±âÇÏ´Ù;±â±ÇÇÏ´Ù;¾çµµÇÏ´Ù;(ÇÚµå
  • release button
    (ÀÚµ¿Â÷ÀÇ ÇÚµåºê·¹ÀÌÅ© µîÀÇ)ÇØÁ¦ ¹öư
  • release copy
    (°ø½Ä ¹ßÇ¥µîÀÇ)»çÀü º¸µµÀÚ·á
  • release date
    release copyÀÇ º¸µµ ½ÃÇÑ
  • release print
    °³ºÀ ¿µÈ­(Çʸ§);ÀÏ¹Ý »ó¿µ¿ë Çʸ§
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á